What is the half-life of ACE-031?

ACE-031 has a half-life of 10-15 days (Fc fusion extends half-life), which is why it's typically administered Once every 2 weeks (based on clinical trial dosing) for optimal therapeutic effect.

How do I reconstitute ACE-031?

Add bacteriostatic water to the peptide vial slowly down the side. Typical reconstitution uses 2-3ml of water for a 5mg vial. Gently swirl, do not shake.

Muscle Growth

Phase 2

ACE-031

Also known as: ActRIIB-Fc, ACE031, ACVR2B-Fc

Overview

Key Facts

Primary Goal: A soluble form of the activin type IIB receptor fused to a human IgG1 Fc domain

A soluble form of the activin type IIB receptor fused to a human IgG1 Fc domain. It functions as a decoy receptor, binding myostatin, activin, GDF-11, and other TGF-beta superfamily ligands before they can signal through their natural receptors. Originally developed for Duchenne muscular dystrophy, trials were halted due to off-target vascular effects. Half-Life 10-15 days (Fc fusion extends half-life) Typical Dose 0.5–3 mg Frequency Once every 2 weeks (based on clinical trial dosing) Cycle Length 8-12 weeks (limited to research context)

Dosing Information

Half-Life

10-15 days (Fc fusion extends half-life)

Typical Dose

0.5–3 mg

Frequency

Once every 2 weeks (based on clinical trial dosing)

Cycle Length

8-12 weeks (limited to research context)

Administration Routes:

subcutaneousintravenous

Storage & Reconstitution

Unreconstituted (Powder)

Temperature2–8°C (36–46°F) or -20°C (-4°F) for long-term

DurationUp to 3 months

Reconstituted (Mixed)

Temperature2–8°C (36–46°F)

Duration2-4 weeks

Research Summary

Phase 2

A Phase II trial in boys with Duchenne muscular dystrophy (NCT01099761) showed dose-dependent increases in lean body mass and bone mineral density. However, the trial was discontinued due to epistaxis and telangiectasias attributed to off-target inhibition of BMP-9/10. Subsequent research by Acceleron led to more selective agents (luspatercept) that avoid the vascular side effects. ACE-031 remains a proof of concept for the ActRIIB pathway in muscle growth.